Abstract 180P
Background
The aim of the study was to assess the impact of integrating an AI solution into our lung nodule program on clinic volumes, patient management, and outcomes.
Methods
We integrated and FDA-cleared AI solution for automated patient identification, tracking and risk stratification into our lung nodule clinic. The AI solution analysed all CT radiology reports and automatically identified the ones with reported lung nodules. Identified patients were contacted by a dedicated nurse navigator and followed. Additionally, the AI solution offered a malignancy score to help risk stratify the lung nodule during clinical evaluation. The number of new nodule patients visiting the clinic, the number of biopsies and surgeries performed, and the numbers of lung cancers diagnosed was compared before and after implementation of the AI tool. For confirmed cancer patients, we compared the stage distribution at diagnosis before and after integration of the AI into our nodule program.
Results
Throughout the 4.5 months after AI implementation, 16.9 new patients per month were seen in our nodule clinic, compared to 12.4 in the same period a year earlier, prior to AI use. The number of invasive diagnostic procedures (biopsies and surgeries) performed on these patients per month increased from 5.8 before AI to 7.6 with AI. Of the 16 confirmed lung cancer patients, 10 (63%)were diagnosed in Stage I with the AI, compared to 7 out of 14 (50%) before AI implementation. The full stage distribution is presented in table.
Table 180P| Stage | Before AI | % | With AI | % |
| I | 7 | 50 | 10 | 63 |
| II | 3 | 21 | 1 | 6 |
| III | 0 | 0 | 0 | 0 |
| IV | 3 | 21 | 2 | 13 |
| Unknown | 1 | 7 | 3 | 19 |
| Total | 14 | 16 |
Conclusions
The Integration of an AI-based automatic identification and risk stratification tool for lung nodule patients into our nodule clinic led to higher patient volumes and helped treat lung cancer patients at early stages, where patients have the greatest chance of long-term survival.
Legal entity responsible for the study
K.A. Lee.
Funding
Has not received any funding.
Disclosure
K.A. Lee: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca. All other authors have declared no conflicts of interest.